The Logic and History of Passive Immunity and Antibody Therapies.
Antibody
Antitoxin
Convalescent plasma
Convalescent serum
Hyperimmune globulins
Monoclonal antibodies
Journal
Current topics in microbiology and immunology
ISSN: 0070-217X
Titre abrégé: Curr Top Microbiol Immunol
Pays: Germany
ID NLM: 0110513
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
21
5
2024
Statut:
aheadofprint
Résumé
This volume takes a broad overview of antibody-based therapies prior to and during the COVID pandemic and examines their potential use in future pandemics. Passive antibody therapy was the first effective antimicrobial treatment and its development in the early twentieth century helped catalyze immunological and microbiological research. During the era of serum therapy (1890-1940) antibody-based therapies were developed against both viral and bacterial diseases. Effective treatment required an understanding of how to quantify antibodies, how to develop serotype-specific sera and recognition of the need to treat early in disease. Thus, although the era of serum therapy essentially ended with the development of small molecule antimicrobial therapy in the 1940s, antibody-based therapies led to important new scientific understanding, while remaining in use for some toxin and venom-caused diseases and in the prevention of outbreaks of viral hepatitis. A renewed interest in antibody-based therapies was seen in the widespread deployment of convalescent plasma and monoclonal antibodies during the COVID-19 pandemic. Convalescent plasma will likely be the first specific therapy during outbreaks with new pathogens for which there is no other therapy. For all forms of antibody-based therapies, effectiveness relies on the key principles of antibody therapy, namely, treatment early in disease with preparations containing sufficient antibody specific to the microbe in question.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Avery OT, Macleod CM, McCarty M (1944) Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type IIII. J Exp Med 79(2):137–158
Barriere SL (1992) The economic impact of HA-1A (Centoxin) against endotoxin. Pharmacoeconomics 2(5):408–413
Blake PA, Feldman RA, Buchanan TM, Brooks GF, Bennett JV (1976) Serologic therapy of tetanus in the United States. JAMA 235:42–44
Borrell B (2008) What is truth serum? Scientific American
Brodie M (1932) A comparison between convalescent serum and non-convalescent serum in poliomyelitis. J Exp Med 55:507–519
Carpenter CM, Boak RA (1936) The treatment of human brucellosis. A review of current therapeutic methods. Medicine 15:103–125
Casadevall A (2017) Crisis in infectious diseases: 2 decades later. Clin Infect Dis off Publ Infect Dis Soc Am 64(7):823–828
Casadevall A, Fang FC (2020) The intracellular pathogen concept. Mol Microbiol 113(3):541–545
Casadevall A, Scharff MD (1994) Serum Therapy” revisited: animal models of infection and the development of passive antibody therapy. Antimicrob Agents Chemotherap 38:1695–1702
Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS et al (2021a) Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife 10
Casadevall A, Pirofski LA, Joyner MJ (2021b) The Principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio 12(2)
Casadevall A, Joyner MJ, Pirofski LA, Senefeld JW, Shoham S, Sullivan D et al (2023) Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. Exp Rev Respir Med 1–15
Cecil RL (1937) Effects of very early serum treatment in pneumococcus Type I pneumonia. JAMA 108:589–692
Cohn EJ, Strong LE et al (1946) Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 68:459–475
Edelson BT, Cossart P, Unanue ER (1999) Cutting edge: paradigm revisited: antibody provides resistance to Listeria infection. J Immunol 163(8):4087–4090
Felton LD (1928) The units of protective antibody in anti-pneumococcus serum and antibody solution. J Infect Dis 43:531–542
Focosi D, McConnell S, Sullivan DJ, Casadevall A (2023) Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment. Drug Resist Updates Rev Commentaries Antimicrob Anticancer Chemother 71:100991
Foshay L (1940) Tularemia: a summary of certain aspects of the disease including methods for early diagnosis and the results of serum treatment in 600 patients. Medicine 19:1–81
Fothergill LRD (1937) Hemophilus influenzae (Pfeiffer bacillus) meningitis and its specific treatment. N Engl J Med 216:587–590
Frank WP, Patton EF, Hamilton PM (1942) Treatment of whooping cough bronchopneumonia. J Pediatr 20:720–722
Gallagher JR (1935) Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health 25:595–598
Glatman-Freedman A, Casadevall A (1998) Serum therapy for tuberculosis revisited: a reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 11:514–532
Griffith F (1928) The significance of pneumococcal types. J Hyg 27(2):113–159
Hattwick MA, Corey L, Creech WB (1976) Clinical use of human globulin immune to rabies virus. J Infect Dis 133(Suppl):A266–A272
Ivens F (1918) The preventive and curative treatment of gas gangrene by mixed serums. BMJ 2(3016):425
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
Lang J, Attanath P, Quiambao B, Singhasivanon V, Chanthavanich P, Montalban C et al (1998) Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered alone or in combination with a purified, Vero-cell rabies vaccine. Acta Trop 70:317–333
Lucchesi PF, Gildersleeve N (1941) The treatment of anthrax. JAMA 14:1506–1508
Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145(8):599–609
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS et al (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211(1):80–90
Maiztegui JI, Fernandez NJ, de Damilano AJ (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2(98154):1216–1217
Manson-Bahr P (1939) The dysenteric disorders. The diagnosis and treatment of dysentery, sprue, colitis, and other diarrheas in general practice. Baltimore: The Williams & Wilkins Co.
Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS Jr, Casadevall A (2003) Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest 112(8):1164–1175
Park WH (1932) Therapeutic use of antipoliomyelitits serum in preparalytic cases of poliomyelitis. JAMA 99:1050–1053
Park WH, Freeman RG (1926) The prophylactic use of measles convalescent serum. JAMA 87:556–561
Pati I, Cruciani M, Candura F, Massari MS, Piccinini V, Masiello F et al (2023) Hyperimmune globulins for the management of infectious diseases. Viruses 15(7)
Plummer N, Liebmann J, Solomon S, Kammerer W, Kalkstein M, Ensworth HK (1941) Chemotherapy versus combined chemotherapy and serum in the treatment of pneumonia: a study of 607 alternated cases. J Am Med Assoc 116(21):2366–2371
Rambar AC (1946) Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. Am J Dis Child 71(1):1–13
Sabin AB (1933) Immediate pneumococcus typing directly from sputum by the Neufeld reaction. JAMA 100:1584–1586
Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM et al (2017) Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. J Infect 74(3):302–309
Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA et al (2021) Access to and safety of COVID-19 convalescent plasma in the United States expanded access program: a national registry study. PLoS Med 18(12):e1003872
Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE et al (2023) Rates among hospitalized patients with COVID-19 treated with convalescent plasma: a systematic review and meta-analysis. Mayo Clinic Proc: Innov Qual Outcomes 7(5):499–513
Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA (1984) Equine antitoxin use and other factors that predict outcome in Type A foodborne botulism. Am J Med 76:794–798
Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue ER, Casadevall A et al (1998) A monoclonal antibody recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci 95:15688–15693
van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S et al (2016) Evaluation of convalescent plasma for Ebola virus disease in guinea. N Engl J Med 374(1):33–42
Wadsworth AB (1929) The hemolytic streptococci and antistreptococcus serum in scarlet fever. Am J Public Health 19:1287–1302
Watson DA, Musher DM, Jacobson JW, Verhoef J (1993) A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 17:913–924
Wesselhoeft C (1933) The present status of serum treatment for acute poliomyelitis. J Pediatr 3:330–351
Wesselhoeft C (1994) Treatment of scarlet fever and diphtheria. Med Clin N Am 19:1389–1429
Wever PC, van Bergen L (2012) Prevention of tetanus during the First World War. Med Humanit 38:78–82
Wortel CH, von der Möhlen MA, van Deventer SJ, Sprung CL, Jastremski M, Lubbers MJ et al (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 166(6):1367–1374
Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324:429–436